Comparing of NanoString Technologies Inc. (NSTG) and DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Both NanoString Technologies Inc. (NASDAQ:NSTG) and DiaMedica Therapeutics Inc. (NASDAQ:DMAC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NanoString Technologies Inc. 27 6.64 N/A -2.74 0.00
DiaMedica Therapeutics Inc. 3 75.83 N/A -0.92 0.00

In table 1 we can see NanoString Technologies Inc. and DiaMedica Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 represents NanoString Technologies Inc. (NASDAQ:NSTG) and DiaMedica Therapeutics Inc. (NASDAQ:DMAC)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
NanoString Technologies Inc. 0.00% -166.7% -51.1%
DiaMedica Therapeutics Inc. 0.00% 0% 0%

Institutional and Insider Ownership

Institutional investors held 90.3% of NanoString Technologies Inc. shares and 13.72% of DiaMedica Therapeutics Inc. shares. Insiders held 0.4% of NanoString Technologies Inc. shares. Competitively, insiders own roughly 8.37% of DiaMedica Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NanoString Technologies Inc. 2.14% 11.92% 26.53% 51.22% 189.26% 121.58%
DiaMedica Therapeutics Inc. -0.53% -23.25% 11.93% -2.51% -54.51% 28.18%

For the past year NanoString Technologies Inc.’s stock price has bigger growth than DiaMedica Therapeutics Inc.


DiaMedica Therapeutics Inc. beats NanoString Technologies Inc. on 4 of the 7 factors.

NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include nCounter Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer pathways gene expression panels, including pathways, immune profiling, and progression panels, as well as nCounter Vantage 3D, other gene expression, miRNA expression, and cancer copy number variation panels. Further, the company offers nCounter Elements reagents that allow users to design customized assays for gene expression, copy number variation, and gene fusions; Master Kits, which include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories, as well as to clinical laboratories and medical centers. NanoString Technologies, Inc. has collaboration with Celgene Corporation; Merck Sharp & Dohme Corp.; Medivation, Inc.; and Astellas Pharma, Inc. The company was founded in 2003 and is headquartered in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.